Answers are grounded in this paper and cite their sources.
Evaluation shows similar tau binding in Down syndrome-associated Alzheimer’s disease and Alzheimer’s disease, suggesting possible diagnostic advancements.
Alzheimer's disease (AD) and Down Syndrome (DS) are characterized by the aggregation of tau tangles. As a novel tau PET tracer in AD, [18F]MK-6240 has the potential in Down syndrome-associated Alzheimer’s disease (DSAD) to elucidate pathophysiology and advance diagnostic strategies. Autoradiography of frontal cortex and temporal cortex postmortem brain slices of DSAD (n = 5), AD (n = 5), and cognitively normal (CN) (n = 5) cases indicated similarly high [18F]MK-6240 binding in DSAD and AD cases. [18F]MK-6240 binding in CN was substantially less than DSAD and AD. Anti-tau immunostains confirmed total tau presence that aligned with the localization of [18F]MK-6240 binding. DSAD and AD cases exhibited higher gray matter (GM)/white matter ratios of 2.8 and 2.5 respectively. For drug effects on [18F]MK-6240 binding, self-displacement by MK-6240 (10 µM) reduced binding by 88% among DSAD cases and 85% among AD cases while IPPI (10 µM) displaced [18F]MK-6240 by 81% and 74% in DSAD and AD cases respectively. KuFal194 (10 µM), a specific phosphokinase inhibitor, minimally displaced [18F]MK-6240 binding. Harmine competed with [18F]MK-6240 with an IC50 value of 290 nM and 92 nM for DSAD and AD cases, respectively. High meninges off-target (non-tau) binding of [18F]MK-6240 was observed in a CN case, comparable to the GM in DSAD and AD. MK-6240 (10 µM) blocked 44% and T807 (10 µM) blocked 30% of meninges binding. Incubation of meninges in the presence of 0.2% polyethyleneimine reduced 70% of [18F]MK-6240 binding. The tau radioligand, [125I]IPPI, an analog of [18F]MK-6240, exhibited minimal binding to CN meninges compared to the DSAD and AD cases. Our findings suggest [18F]MK-6240 to be selective tau imaging agent in DSAD and AD, harmine to uniquely compete with [18F]MK-6240 binding in DSAD and provide preliminary insights to the off-target nonspecific binding of [18F]MK-6240 in postmortem meninges.
No takes yet. Share an insight, caveat, or question.
Karim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: